Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.01 - $1.36 $101 - $136
-100 Closed
0 $0
Q3 2019

Aug 13, 2024

SELL
$0.79 - $2.47 $79 - $247
-100 Closed
0 $0
Q1 2019

Aug 13, 2024

BUY
$5.63 - $7.84 $563 - $784
100 New
100 $599,000
Q2 2018

Aug 13, 2024

SELL
$16.46 - $20.33 $27,191 - $33,585
-1,652 Reduced 94.29%
100 $2 Million
Q1 2018

Aug 14, 2024

BUY
$17.08 - $25.64 $1,707 - $2,564
100 New
100 $1.75 Million
Q1 2018

Aug 13, 2024

BUY
$17.08 - $25.64 $28,216 - $42,357
1,652 Added 1652.0%
1,752 $1.75 Million
Q4 2017

Aug 13, 2024

BUY
$21.47 - $27.8 $2,147 - $2,780
100
100 $2.47 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $255M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.